Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
RMD Open|January 28, 2021
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practiceJulia M Weijers, Wieland D Müskens, Piet L C M van Riel
Nederlands Tijdschrift Voor Geneeskunde|October 9, 2024
[Systemic side effects of locally administered corticosteroids]Wieland D Müskens, Marianne K Dees, M M L Stikkelbroeck, et al.
The Journal of Rheumatology|November 2, 2020
Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?Wieland D Müskens, Sanne A A Rongen-van Dartel, Piet L C M van Riel, et al.
Mediterranean Journal of Rheumatology|June 12, 2020
Biosimilars in the management of chronic inflammatory diseases: The Dutch experienceWieland D Müskens, Sanne A A Rongen-van Dartel, Eddy M M Adang, et al.
Rheumatology Advances in Practice|October 2, 2020
One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatologyWieland D Müskens, Sanne A A Rongen-van Dartel, Steven Teerenstra, et al.
Rheumatology Advances in Practice|March 10, 2021
Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilizationWieland D Müskens, Sanne A A Rongen-van Dartel, Carine Vogel, et al.
Clinical Pharmacology and Therapeutics|October 23, 2025
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do MatterAmy C D Peeters, Maike H M Wientjes, Wieland D Müskens, et al.
Pageof 1